Dutch NLC has 20m in first close of new Health Impact Fund
Dutch venture builder NLC has announced a 20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
French Carthera closes 37.5m Series B financing round
/in News/by Thomas GabrielczykCarthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its 37.5m […]
Donaldson Acquires Belgian Univercells Technologies for 138m
/in News/by Thomas GabrielczykDonaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative biomanufacturing solutions for cell […]
Gleamer raises 27m in Series B funding round
/in News/by Thomas GabrielczykFrench AI-powered radiography diagnostics specialist Gleamer SAS has raises 27m in Series B round to expand its portfolio and accelerate its expansion.
Centogene and Lifera kick-off joint venture
/in News/by Thomas GabrielczykMulti-omics diagnostics specialist Centogene NV has received 30m to form a joint venture with PIF-owned pharmaceutical company Lifera in Saudi-Arabia.
Astraveus SAS bags 16.5m in seed financing
/in News/by Thomas GabrielczykFrench cell and gene therapy manufacturing specialist Astraveus SAS had raises 16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform.
New BIOTECH insight newsletter out
/in News/by Thomas GabrielczykBreaking news from biotechnology and the German stock market are in the focus of the new issue of BIOTECH Insight, the newsletter of Deutsche Börse AG.
Santhera licences vamorolone rights to Catalyst Pharmaceuticals
/in News/by Thomas GabrielczykSanthera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.
BioSenic halts ALLOB development
/in News/by Thomas GabrielczykBioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.
Neogap fully takes over TCER Oncology shares
/in News/by Thomas GabrielczykSwedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.